BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23913207)

  • 1. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
    Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
    Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
    Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R
    PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
    Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
    Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative network analysis of TCGA data for ovarian cancer.
    Zhang Q; Burdette JE; Wang JP
    BMC Syst Biol; 2014 Dec; 8():1338. PubMed ID: 25551281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
    Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
    Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
    Singh AK; Chandra N; Bapat SA
    Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer.
    Bapat SA; Krishnan A; Ghanate AD; Kusumbe AP; Kalra RS
    Cancer Res; 2010 Jun; 70(12):4809-19. PubMed ID: 20530682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
    Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas.
    Benetkiewicz M; Wang Y; Schaner M; Wang P; Mantripragada KK; Buckley PG; Kristensen G; Børresen-Dale AL; Dumanski JP
    Genes Chromosomes Cancer; 2005 Mar; 42(3):228-37. PubMed ID: 15578687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
    Tsuda H; Birrer MJ; Ito YM; Ohashi Y; Lin M; Lee C; Wong WH; Rao PH; Lau CC; Berkowitz RS; Wong KK; Mok SC
    Cancer Genet Cytogenet; 2004 Dec; 155(2):97-107. PubMed ID: 15571795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
    Barton CA; Hacker NF; Clark SJ; O'Brien PM
    Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
    Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
    Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma.
    Sung CO; Choi CH; Ko YH; Ju H; Choi YL; Kim N; Kang SY; Ha SY; Choi K; Bae DS; Lee JW; Kim TJ; Song SY; Kim BG
    Cancer Genet; 2013 May; 206(5):145-53. PubMed ID: 23726144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression.
    de Tayrac M; Etcheverry A; Aubry M; Saïkali S; Hamlat A; Quillien V; Le Treut A; Galibert MD; Mosser J
    Genes Chromosomes Cancer; 2009 Jan; 48(1):55-68. PubMed ID: 18828157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
    Wei SH; Chen CM; Strathdee G; Harnsomburana J; Shyu CR; Rahmatpanah F; Shi H; Ng SW; Yan PS; Nephew KP; Brown R; Huang TH
    Clin Cancer Res; 2002 Jul; 8(7):2246-52. PubMed ID: 12114427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
    Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
    Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.